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Multiple sclerosis (MS) is a complex auto-immune disorder of the central nervous
system (CNS) that involves a range of CNS and immune cells. MS is characterized
by chronic neuroinflammation, demyelination, and neuronal loss, but the molecular
causes of this disease remain poorly understood. One cellular process that could
provide insight into MS pathophysiology and also be a possible therapeutic
avenue, is autophagy. Autophagy is an intracellular degradative pathway essential
to maintain cellular homeostasis, particularly in neurons as defects in autophagy
lead to neurodegeneration. One of the functions of autophagy is to maintain
cellular homeostasis by eliminating defective or superfluous proteins, complexes, and
organelles, preventing the accumulation of potentially cytotoxic damage. Importantly,
there is also an intimate and intricate interplay between autophagy and multiple aspects
of both innate and adaptive immunity. Thus, autophagy is implicated in two of the main
hallmarks of MS, neurodegeneration, and inflammation, making it especially important
to understand how this pathway contributes to MS manifestation and progression.
This review summarizes the current knowledge about autophagy in MS, in particular
how it contributes to our understanding of MS pathology and its potential as a novel
therapeutic target.
Keywords: autophagy, multiple sclerosis, neurodegeneration, inflammation, resolution
INTRODUCTION
Autophagy is a lysosomal degradation system for damaged or unwanted organelles, aggregates, and
long-lived proteins, which is important for cellular homeostasis (Choi et al., 2013). This process is
responsible for nutrient supply under starved conditions by recycling the metabolites composing
cellular components (Lahiri et al., 2019). Autophagy is also involved in a multitude of other
physiological functions, including the regulation of innate and adaptive immune responses (Beau
et al., 2011; Levine et al., 2011). In recent years, the involvement of autophagy in several pathological
conditions, such as neurodegenerative disorders and autoimmune diseases, has become evident as
well (Mizushima et al., 2008; Law et al., 2010; Ravikumar et al., 2010; van Beek et al., 2018; Yin et al.,
2018; Levine and Kroemer, 2019).
Multiple sclerosis (MS) is a demyelinating auto-immune disorder of the central nervous
system (CNS), which is driven by a complex interaction between environmental, genetic,
and immunological factors. MS is characterized by the interplay of neuroinflammatory and
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neurodegenerative processes, resulting in progressive disability
of patients (Dyment et al., 2006; Sawcer et al., 2011; Dobson
and Giovannoni, 2019). Although this disease has been viewed
for a long time as a T-cell-mediated autoimmune disease, recent
investigations have uncovered that MS is a complex disorder that
involves many cell types, including both other immune cells,
such as dendritic and B-cells, and CNS cells, including neurons
and glial cells. Most patients suffer from a relapsing-remitting
disease course that is characterized by bouts of inflammation and
neurodegeneration, which eventually transitions into progressive
MS (Dobson and Giovannoni, 2019). Yet, the precise molecular
causes underlying MS as well as the mechanisms driving either
relapsing-remitting or progressive disease progression, remain
largely unknown. There is no cure for MS and current treatments
are mainly focused on the relapsing-remitting phase of the disease
and they primarily target the immune system.
In this review, the function of autophagy in regulating
neuroinflammation and neurodegeneration in MS is discussed,
with a particular focus on how autophagy interferes with the
regulation and functioning of different cell types that contribute
to the pathophysiology of this devastating disease.
THE REGULATION AND MECHANISM OF
AUTOPHAGY
Different types of autophagy have been described based on their
differences in regulation, type of cargo, and the lysosomal delivery
mechanism: chaperone-mediated autophagy, microautophagy,
and macroautophagy (Feng et al., 2018). These processes are
described in detail elsewhere (Martinez-Vicente and Cuervo,
2007; Cuervo, 2010; Li et al., 2012; Feng et al., 2014) and here
we focus on the regulation of macroautophagy since this process
is best described in brain disorders (Nixon, 2013; Liang and Le,
2015; Menzies et al., 2017; van Beek et al., 2018; Yin et al., 2018;
Levine and Kroemer, 2019; Stamatakou et al., 2020).
Macroautophagy, hereafter referred to as autophagy, is
characterized by the sequestration of cytoplasmic substrates
by double-membrane vesicles called autophagosomes, which
originates from membranous cisterna, the phagophores,
generated de novo upon autophagy induction. Completed
autophagosomes then fuse with lysosomes to deliver their cargo
in the interior of this hydrolytic organelle. The metabolites
resulting from the degradation of the autophagosomal cargoes
are recycled back to the cytosol for the synthesis of new proteins
or are used for the generation of energy (Lahiri et al., 2019).
Autophagy is a highly conserved and dynamic process that
can be subdivided into five sequential steps; (i) induction
and nucleation of the phagophore, (ii) phagophore elongation,
(iii) phagophore closure and autophagosome maturation, (iv)
autophagosome fusion, and (v) cargo degradation (Figure 1).
These steps involve a cascade of events that are mediated
by proteins, most of which have been named as autophagy-
related (ATG) proteins (Figure 1; Nakatogawa, 2020). Upon
autophagy induction, the ULK kinase complex, which consists
of the serine/threonine kinases ULK1 or ULK2, FIP200, ATG13,
and ATG101, gets activated through self-phosphorylation and
stimulates the formation of the class III phosphatidylinositol
3-kinase (PI3KC3) complex (Nakatogawa, 2020). The PI3KC3
complex consists of the BECLIN1, VPS34, VPS15, ATG14,
and NRBF2 subunits, and generates phosphatidylinositol 3-
phosphate (PI3P) on the phagophore membrane (Nakatogawa,
2020). PI3P is key for the recruitment of several downstream
ATG proteins that bind to this lipid, such as WIPI2 (Qian
et al., 2017). Together with the ULK complex and ATG9A-
positive vesicles, PI3KC3 catalyzes the nucleation of the
phagophore (Figure 1; Nakatogawa, 2020). The elongation
process involves two ubiquitin (Ub)-like conjugation systems
that is composed by several ATG proteins. The first system
involves the activation of ATG12 by ATG7 which is then
transferred via ATG10 to ATG5 to generate the ATG12-
ATG5 conjugate, which associates to ATG16L1. This is then
recruited to the phagophore membrane by WIPI2, forming a
multimeric complex (Figure 1; Nakatogawa, 2020). In parallel,
ATG7, ATG4, and ATG3 are involved in another system
that is responsible for the conjugation of LC3 proteins to
phosphatidylethanolamine (PE). This conjugation occurs on the
phagophore membrane and is guided by the ATG12-ATG5-
ATG16L1 complex (Figure 1; Nakatogawa, 2020). Conjugated
LC3 proteins are present on the internal and external surface
of the expanding phagophore to mediate the expansion and
closure of the autophagosome (Nakatogawa, 2020). Once
autophagosomes are completed, they traffic toward lysosomes
and fuse with these organelles through an event mediated
by SNARE proteins and other fusion co-factors, to form the
so-called autolysosomes (Figure 1). After fusion, the content
of the autophagosome is exposed to lysosomal enzymes and
the metabolites generated by degradation are recycled to the
cytosol via permeases on the limiting membrane of lysosomes
(Lahiri et al., 2019).
Autophagy can either be non-selective, referred to as
bulk autophagy and it is activated, e.g., under starved
conditions to recycle cellular components in an apparent random
manner, or selective. During selective types of autophagy,
damaged or superfluous organelles but also other structures,
including mitochondria (mitophagy), lipid droplets (lipophagy),
ribosomes (ribophagy), and invading pathogens (xenophagy),
are specifically and exclusively sequestered by autophagosomes
(Kirkin and Rogov, 2019). The pool of PE-conjugated LC3
proteins in the inner surface of phagophores promote the
cargo engulfment via LC3-interacting regions (LIR) that are
present on the so-called autophagy receptors, some of which
are soluble (e.g., p62/SQSTM1, NDP52, or OPTN) and bind
to ubiquitinated cargo, while other are present on organelles
(e.g., NIX on mitochondria or FAM134B on the endoplasmic
reticulum) (Figure 1; Kirkin and Rogov, 2019). This recognition
system allows selective degradation of specific cargo.
Under nutrient-rich conditions, autophagy is negatively
regulated by the mammalian target of rapamycin complex
1 (mTORC1) that phosphorylates and inactivates the ULK
kinase complex (Figure 1; He and Klionsky, 2009; Zachari and
Ganley, 2017). Upon removal of nutrients or energy, autophagy
is induced via inhibition of mTORC1 and/or through direct
phosphorylation and activation of the ULK kinase complex by
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FIGURE 1 | Schematic overview of autophagy. Under nutrient rich conditions, the autophagy process is negatively regulated by mTORC1, whose activity can be
inhibited through AMPK activation, starvation, hypoxia, or stress. The latter lead to a de-repression of the ULK kinase complex, which self-activates through
autophosphorylation and stimulates the recruitment and activation of the PI3KC3 complex. PI3KC3 produces PI3P on the phagophore membrane, which is needed
for the recruitment of the ubiquitin complexes to the membrane of the autophagosome. The nucleation is mediated by ATG9A vesicles, ULK, and PI3KC3
complexes. The autophagosome formation requires two Ub-like conjugation systems. LC3 proteins are post-translationally processed by ATG4 proteases and upon
induction of autophagy, they are activated by ATG7 and ATG3 enzymes and conjugated with PE. This event is guided by a complex formed by the second Ub-like
conjugation system. ATG7 activates ATG12, which is then covalently linked to ATG5 by ATG10 and subsequently associates with ATG16L1 to form a multimeric
complex. This complex is anchored onto the phagophore by interacting with the PI3P effector protein WIPI2. The proteins on the external surface dissociate after
completion, whereas LC3-PE permanently integrates on the internal surface of the membrane. The complete autophagosome ultimately fuses with lysosomes in a
SNARE-mediated manner to form an autolysosome, in which the autophagosomal cargo is degraded by lysosomal enzymes.
adenosine monophosphate-activated protein kinase (AMPK),
resulting in the activation of the downstream machinery of
autophagy and consequently initiating this process (Figure 1; He
and Klionsky, 2009; Puente et al., 2016; Keller and Lünemann,
2017; Zachari and Ganley, 2017). The modulation of these kinases
is currently the major strategy to induce autophagy in vivo and in
patients (Menzies et al., 2017; Djajadikerta et al., 2020).
AUTOPHAGY AND
NEURODEGENERATION
A hallmark shared by many neurodegenerative diseases of the
CNS is neuronal loss, which can have a range of causes, from the
formation of cytotoxic aggregates to mitochondrial dysfunction
and/or iron accumulation (Wong and Holzbaur, 2014).
Neurons heavily depend on autophagy for their survival and
maintenance of homeostasis (Hara et al., 2006; Komatsu et al.,
2006), and therefore it is not surprising that dysfunction of
this process causes neurodegenerative diseases (Fujikake et al.,
2018). Defects in different steps of the autophagy process, such
as impaired autophagosome formation, inhibited autolysosome
formation, or disrupted lysosomal function have been observed,
e.g., Alzheimer’s disease (AD), Huntington’s disease (HD), and
Parkinson’s disease (PD) (Nixon, 2013; Menzies et al., 2017).
Consistently, loss of Atg7 or Atg5 in the CNS of mice
or neurons causes neurological defects and severe damage to
neurons (Komatsu et al., 2006; Cuervo, 2010; Nixon, 2013;
Stavoe and Holzbaur, 2019). Autophagy is important to degrade
physiological and potentially cytotoxic protein aggregates and
has a protective effect against the disease-associated aggregates
characterizing AD, HD, and PD (Ravikumar et al., 2004; Nixon
and Yang, 2011; Nixon, 2013; Menzies et al., 2017; Fujikake
et al., 2018). The conditional deletion of ATG genes in mice
leads to the accumulation of aggregates (Hara et al., 2006;
Komatsu et al., 2006) and progressive neuronal death in different
areas of the brain (Menzies et al., 2017). In MS lesions,
extracellular aggregates of fibronectin are observed (Stoffels
et al., 2013), however, it remains to be determined whether
their appearance is connected to a deficient ATG machinery. In
addition to aggregate removal, autophagy can degrade damaged
mitochondria, which when impaired, can also contribute to
neuronal damage and death (Wong and Holzbaur, 2014).
Consequently, pharmacological induction of autophagy showed
beneficial effects in a wide range of neurodegenerative diseases,
such as HD and AD (Menzies et al., 2017).
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Besides the intracellular defects in neurons that lead to
neuronal damage, external stimuli can also cause neuronal
loss. For example, neuroinflammation is often observed in
neurodegenerative diseases, where it contributes to neuronal
damage (Rubinsztein et al., 2015), and autophagy is emerging
as an important modulator of inflammation (discussed below).
Moreover, autophagy is critical for debris clearance, and its
impairment delays myelin debris clearance after nerve injury
(Jang et al., 2016), which prevents efficient remyelination and
further leads to neuronal damage and neurodegeneration, which
are typical in MS.
AUTOPHAGY AND INFLAMMATION
The immune system is essential to maintain systemic health by
eliminating pathogens and preventing infections, and damaged
cells. The inflammatory response of immune cells plays an
essential role in this process and involves many cell types.
Autophagy has been implicated in both the innate and adaptive
immune response, playing a role in pathogen removal, antigen
presentation, cytokine production, lymphocyte survival, and
development of specific cell types (Miller et al., 2008; Levine
et al., 2011; Shi et al., 2012; Deretic et al., 2013; Qian et al., 2017;
Yin et al., 2018). The link between autophagy and inflammation
is complex and reciprocal since they can either induce or
suppress each other through different mechanisms (Levine et al.,
2011; Deretic et al., 2013; Liang and Le, 2015). Therefore, it
is not surprising that autophagy has been functionally and/or
pathologically connected to several neuroinflammatory diseases,
including AD, HD, amyotrophic lateral sclerosis (ALS), and MS
(Levine et al., 2011; Muller et al., 2017; Yin et al., 2018).
Autophagy can be induced by different pro-inflammatory
stimuli, such as toll-like receptor (TLR) activation,
damage-associated molecular patterns (DAMPs), and pathogen-
associated molecular patterns (PAMPs) (Harris and Keane,
2010; Levine et al., 2011; François et al., 2014; Liang and Le,
2015; Yin et al., 2018). On the other hand, it can be inhibited
by Th2-associated pro-inflammatory cytokines, such as IL-
4 and IL-13 (Harris et al., 2007; Harris and Keane, 2010;
Park et al., 2011; Deretic et al., 2013). In its turn, autophagy
inhibits, for example, the inflammatory IL-1β and IL-18
responses (Shi et al., 2012; Liang and Le, 2015; Zhang H.
et al., 2016) by degrading inflammasomes (Shi et al., 2012;
Deretic et al., 2013). Further, it also prevents the production of
reactive oxygen species (ROS) that activate inflammasomes by
eliminating damaged mitochondria (Qian et al., 2017). Overall,
autophagy is a negative feedback regulator of the immune
system, participating in the resolution of inflammation and
returning it to homeostasis (Levine et al., 2011). However,
autophagy is also implicated in T-cell survival and polarization,
the differentiation and survival of antibody-secreting plasma
cells, and the enhancement of antigen presentation in dendritic
cells (DCs) (Pengo et al., 2013; Conway et al., 2013; Deretic
et al., 2013; Qian et al., 2017), which are all processes that
form the core of immune responses. Thus, dysregulation of
autophagy can prolong and make persisting inflammatory
responses after an insult, possibly leading to autoimmune and
inflammatory diseases.
Genome-wide association studies have revealed the
connection of several ATG genes with inflammatory and
autoimmune disorders (Muller et al., 2017). It is important
to note that the regulation of autophagy varies in different
inflammatory diseases. Pharmacological inducers of autophagy
appear to be protective against psoriasis (Varshney and Saini,
2018) and inflammatory bowel disease (Saitoh et al., 2008),
whereas inhibition of this process ameliorates illnesses such as
systemic lupus erythematosus (Clarke et al., 2015), rheumatoid
arthritis (Lin et al., 2013), and MS (Kovacs et al., 2012).
The crosstalk between autophagy and the immune system
emphasizes the importance of this process in the pathogenesis of
autoimmune disorders, including MS.
AUTOPHAGY AND MS
Multiple sclerosis is characterized by inflammation,
demyelination, and neurodegeneration, all processes that
have been connected to autophagy, and therefore, investigating
autophagy in the context of MS is relevant. In blood samples
from MS patients, several ATG genes involved in multiple
steps of the autophagy process were differently expressed;
ATG9A and BECN1 were downregulated, while ULK1, ULK2,
and ATG5 were upregulated (Igci et al., 2016). In addition, in
experimental autoimmune encephalomyelitis (EAE), an MS
mouse model, LC3 and BECLIN1 protein levels were reduced
while those of p62/SQSTM1 were increased in the spinal cords
of these animals. Moreover, inhibition of mTORC1 ameliorated
disease severity (Boyao et al., 2019), suggesting that autophagy
is negatively affected in EAE mice. Inhibition of autophagy can
also result in the accumulation of damaged mitochondria and
the production of ROS (Chen et al., 2008; Hassanpour et al.,
2020), which both contribute to the demyelination process
in MS. Another approach to enhance autophagy is through
caloric restriction, where cycles of a fasting-mimicking diet are
applied, and this regime has been shown to ameliorate disease
severity and stimulates remyelination in both EAE mice and
relapsing-remitting MS patients (Choi et al., 2016).
Importantly, a few studies have indicated that autophagy is
differently involved in both relapsing and progressive forms
of MS. In a cohort study, autophagic activity was increased
in relapsing-remitting MS patients (Hassanpour et al., 2020),
and ultrastructural analyses revealed the presence of synaptic
vesicle-containing autophagosomes in the dentate nucleus from
a chronic MS patient (Albert et al., 2017), suggesting a
pathological role of autophagy in MS. Treatment with an
mTORC1 inhibitor, however, resulted in beneficial effects in
both relapsing-remitting EAE mice (Esposito et al., 2010) and
patients with MS (Hassanpour et al., 2020). This emphasizes the
importance to further elucidate how autophagy is involved in
different forms of MS.
Although autophagy is important to maintain homeostasis
in all cell types, its requirement for other functions and
consequently its regulation varies in the different cell types and
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consequently its regulation differs as well (Liang and Le, 2015).
This aspect also emerges in the context of MS, in which autophagy
appears to contribute to the pathology in DCs, T-cells and B-cells,
while it has a protective role in neurons and glial cells.
Dendritic Cells
DCs are the main peripheral antigen-presenting cells (APCs)
that can trigger a T-cell response (Nuyts et al., 2013). Antigen
presentation is required for both T-cell development and their
activation, through the expression of surface molecules and
cytokine secretion from DCs (Yogev et al., 2012). DCs are the
most efficient APCs for reactivating myelin-specific CD4+ T-cells
in the CNS (Yogev et al., 2012; Mohammad et al., 2013), and they
are present in cerebrospinal fluid (CSF) and CNS lesions of MS
patients (Nuyts et al., 2013).
It was hypothesized that removing DCs could inhibit EAE
development, however, depletion of DCs in mice showed a
stronger inflammatory response and enhanced EAE severity
(Yogev et al., 2012). The levels of regulatory T-cells (Treg)
were also lower (Yogev et al., 2012; Mohammad et al., 2013),
confirming the important role of DCs in regulating T-cell
homeostasis. In addition, a study where major histocompatibility
complex (MHC) class II expression was only restricted to DCs,
revealed that DCs are sufficient to present antigens to T-cells
in order to mediate CNS inflammation in EAE mice (Greter
et al., 2005). Altogether, these data show that the status of DCs
is crucial for MS development, i.e., steady-state DCs play a
protective role by inducing self-tolerance and by differentiating
Treg cells, whereas activated DCs are responsible for the stronger
immunogenic response by activating CD4+ T-cells (Greter et al.,
2005; Yogev et al., 2012; Mohammad et al., 2013). These
observations have raised the question whether the molecular
pathway of antigen presentation to CD4+ T-cells could be
modulated to prevent immune activation.
DCs phagocytose antigens and after their processing, the
resulting peptides are presented on MHC class I and II molecules
on the cell surface to activate CD8+ and CD4+ T-cells,
respectively. During immune activation, autophagy is involved in
host protection by delivering cytoplasmic antigens to lysosomes
for subsequent presentation on MHC class II (Paludan et al.,
2005; Bhattacharya et al., 2014; Yang et al., 2015; Schmid et al.,
2007). In addition, extracellular compounds are degraded by
LC3-associated phagocytosis (LAP), which depends on several
ATG proteins (Lai and Devenish, 2012). This suggests that
the ATG machinery might be involved in the myelin peptide
presentation on MHC class II molecules and subsequently
activation of CD4+ autoreactive T-cells (Figure 2a). Studies
supporting this hypothesis showed that DCs lacking Atg5 or
Atg7 reduced the incidence and severity of EAE (Bhattacharya
et al., 2014; Keller et al., 2017; Hassanpour et al., 2020).
The absence of ATG proteins in DCs caused a reduction of
myelin peptide presentation and less activated CD4+ T-cells
during EAE, however, it did not affect the levels of CD8+
T-cells (Bhattacharya et al., 2014; Keller et al., 2017; Hassanpour
et al., 2020). Interestingly, autophagy-deficient DCs completely
inhibited the development of EAE via adoptive transfer of
primed encephalitogenic T-cells (Keller et al., 2017), suggesting
that ATG proteins are important for the activation of primed
myelin-specific CD4+ T-cells. Moreover, deletion of ATG genes
in DCs did not affect other functions of DCs (Lee et al., 2010;
Bhattacharya et al., 2014; Keller et al., 2017), indicating their
specific importance for antigen presentation. Pharmacological
inhibition of autophagy with chloroquine before EAE onset
delayed disease progression and reduced EAE severity when
administered during EAE development (Bhattacharya et al.,
2014). However, this approach is not specific for autophagy and
also affects LAP as well as other processes relying on lysosomal
proteolytic activity. Therefore, further investigation is necessary
to reveal whether autophagy is involved in antigen presentation
of myelin-derived peptides in DCs or whether this is regulated by
ATG protein-dependent phagocytic processes.
Altogether, DCs have both protective and pathological roles
in MS, and autophagy could be important for the CD4+ T-cell-
mediated autoimmune responses, thereby contributing to the
pathological traits of DCs in MS.
T-Cells
T-cells originate from bone marrow-derived hematopoietic stem
cells. Lymphoid precursor cells migrate via the blood to the
thymus where they develop into mature T-lymphocytes (Jia and
He, 2011; Parekh et al., 2013; Bronietzki et al., 2015). T-cells are
part of the adaptive immune system and are important players
in both the development and modulation of inflammation. It
is generally accepted that autoreactive T-cells against myelin in
the CNS are key contributors to MS pathology (Group Nature
Publishing, 2001; Glass et al., 2010; Liang and Le, 2015). The
current notion is that T-cells are activated in the periphery by
APCs, in particular by DCs, and differentiate into autoreactive
T-cells. These autoreactive T-cells enter the CNS by damaging
the blood-brain barrier, and in the CNS, they get reactivated
and amplified (Group Nature Publishing, 2001; Glass et al., 2010;
Chihara, 2018), and attack myelin sheaths of axons, resulting in
denuded axons and ultimately in neuronal loss (Group Nature
Publishing, 2001; Glass et al., 2010). Although, MS is thought to
be a CD4+ T-cell-mediated autoimmune disease, an increasing
number of studies has reported a role of CD8+ T-cells in
the initial relapse phase of MS since the frequency of CD8+
T-cells appearance in lesions was increased (Friese and Fugger,
2009; Salou et al., 2015). Several studies also highlighted the
importance of T-cells in MS pathology; they showed that the
balance between CD4+ T-cells, CD8+ T-cells, and Tregs is
disturbed (Fletcher et al., 2010; Chihara, 2018). This might be
due to higher levels of autoreactive T-cells that showed increased
proliferation and prolonged survival in MS patients (Sawcer et al.,
2011; Igci et al., 2016).
During the past decades, autophagy has been implicated in
various biological processes of T-cells, such as maintenance of
T-cell homeostasis, differentiation, and activation (Li et al., 2006;
Pua and He, 2007; Pua et al., 2007, 2009; Botbol et al., 2016;
Paunovic et al., 2018; Macian, 2019). The expression levels of
the ATG5 gene in T-cells from MS patients are increased in
blood and brain sections (Alirezaei et al., 2009; Yang et al., 2015),
indicating a possible involvement of autophagy in the activation
of autoreactive T-cells. Consistently, autophagosomes were only
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FIGURE 2 | The possible link between autophagy and MS in different cell types. Autophagy is critical in the development and function of cells that play an important
role in MS pathology. The left side of the diagram shows the effects of an enhancement of autophagy in T-cells, B-cells and DCs, while the right side depicts the
effects of autophagy downregulation in neurons, microglia and other glial cells. (a) Increased myelin processing and antigen presentation to CD4+ autoreactive
T-cells in DCs by either autophagy or LAP. (b) Prolonged survival of activated CD4+ and CD8+ T-cells due to low levels of ROS, resulting in proliferation and secretion
of pro-inflammatory cytokines. (c) Productive processing of antigens in EBV-infected B-cells, that results in citrullinated peptides that are presented as neo-epitopes
to CD8+ T-cells, and prolonged survival of B-cells by degrading damaged mitochondria. (d) Defective autophagy in neurons results in increased ROS levels and
aggregate formation. (e) Insufficient clearance of damaged mitochondria, inflammasomes, and myelin debris in microglia, promotes a pro-inflammatory phenotype
caused by autophagy or LAP. (f) Decreased tissue repair and secretion of pro-inflammatory cytokines by astrocytes (red), aggravates the inflammatory response and
impaired remyelination by OLs (purple).
detected in CD4+ T-cells after T-cell receptor activation, and
not in resting, naïve cells (Li et al., 2006; Hubbard et al.,
2010; Macian, 2019). Mice experiments with either Atg5- or
Atg7-deficient CD4+ and CD8+ T-cells showed indeed multiple
defects, including reduced survival and a defect in T-cell
proliferation in response to antigen stimulation (Pua et al., 2007;
Alirezaei et al., 2009; Keller and Lünemann, 2017; Paunovic et al.,
2018; Yin et al., 2018). Beclin1-deficient CD4+ T-cells prevented
EAE development in mice, and T-cells were absent in the CNS
(Alirezaei et al., 2009; Kovacs et al., 2012; Yin et al., 2018).
It has also been suggested that autophagy regulates cell
death in activated T-cells (Kovacs et al., 2012). Beclin1-
deficient CD4+ T-cells are more susceptible to apoptotic
stimuli since they accumulate cell death-related proteins, such
as procaspase-3, procaspase-8, and BCL2-interacting mediator
(BIM). In particular, cell death-related proteins have been
found in autophagosomes, and these proteins accumulated in
autophagy-deficient T-cells (Li et al., 2006; Pua and He, 2007;
Trapp and Nave, 2008; Pua et al., 2009; Kovacs et al., 2012;
Salminen et al., 2013). This suggests a pro-survival function
of autophagy in activated T-cells through the turnover of cell
death-related proteins, which then will prolong their survival
and consequent rapid amplification in the CNS that will initiate
a persisting immune response (Figure 2b; Botbol et al., 2016).
In addition, other reports have revealed that organelle turnover
in T-cells critically depends on autophagy. Specifically, ER
and dysfunctional mitochondria accumulate in T-cells when
autophagy is blocked, which in turn leads to an increase in ROS
levels and consequent cell death (Pua et al., 2009; Hubbard et al.,
2010; Jia and He, 2011; Kovacs et al., 2012; Macian, 2019). An
important finding is that subtypes of T-cells such as Th17 and
Th1 are not equally susceptible to cell death after Beclin1-deletion
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(Kovacs et al., 2012), which might be due to the importance of
autophagy in cell survival in different subsets of T-cells, or other
roles of Beclin1 outside the context of autophagy.
These findings show that enhanced autophagy promotes
T-lymphocyte survival and proliferation, thereby positively
contributing to MS pathogenesis.
B-Cells
B-cells play an important role in immune processes by generating
antibodies that are directed to pathogens (Lehmann Horn et al.,
2013; Li et al., 2018). Moreover, B-cells are recognized as APCs
and thereby contribute to the regulation of immune processes
(Hirotani et al., 2010; von Büdingen et al., 2015; Arneth, 2019).
The crucial role of B-cells in MS pathology became clear when
depletion of B-cells in MS patients with anti-CD20 antibodies
led to the suppression of an inflammatory response, reducing
the formation of new lesions and disease progression (Hauser
et al., 2008; Gelfand et al., 2017; Mulero et al., 2018; Sospedra,
2018; Arneth, 2019). Similar to DCs and T-cells, B-cells consist of
different subpopulations. B-cells in MS patients show increased
secretion of pro-inflammatory cytokines (Bar-Or et al., 2010) and
a deficiency in IL-10 production (Duddy et al., 2007), suggesting
a perturbed balance between pro-inflammatory and regulatory
B-cells, respectively. It is not fully understood how these B-cells
contribute to MS pathology.
One environmental risk factor that has been linked to MS
is the Epstein–Barr virus (EBV) (Sospedra, 2018). EBV infects
B-cells, which in turn cross-present autoantigens that can activate
T-cells against myelin (Bar-Or et al., 2020). The link between EBV
and MS development is quite strong since nearly all MS patients
had a past EBV infection (Ascherio and Munger, 2010; Guan
et al., 2019). It appears that EBV infection during adolescence is
a prerequisite to develop MS, although not sufficient on its own
(Ascherio and Munger, 2010; Guan et al., 2019; Bar-Or et al.,
2020). B-cells from MS patients show an increased expression
of APC-related markers (Sospedra, 2018; Guan et al., 2019)
and experiments in EAE mice uncovered that EBV upregulates
antigen cross-presentation of infected B-cells to CD8+ T-cells
(Dunham et al., 2017; Jakimovski et al., 2017). These results
indicate that EBV influences the antigen presentation of B-cells.
This notion is also supported by EAE animal experiments,
where uninfected B-cells prevented autoimmunity by degrading
self-antigens, while these antigens, which are generated by the
productive processing of myelin oligodendrocyte glycoprotein
(MOG), are presented to autoreactive T-cells in EBV infected
B-cells, thereby inducing an immune activity (Thorley-Lawson
and Mann, 1985; Livingston et al., 1997; Jagessar et al., 2016;
Dunham et al., 2017; Jakimovski et al., 2017; Morandi et al., 2017;
Guan et al., 2019).
It has been suggested that the productive processing of
antigens results from the citrullination of peptides, and this
is enhanced by an EBV infection (’t Hart et al., 2016;
Morandi et al., 2017; Bar-Or et al., 2020). Citrullination is
a posttranslational modification that converts arginine into
citrulline, this conversion is relevant for antigen presentation
because it generates neo-epitopes that can be recognized
by the immune system (Guan et al., 2019). Autophagy is
responsible for the generation and processing of citrullinated
peptides (Ireland and Unanue, 2011; Münz, 2016; Morandi
et al., 2017), resulting in neo-epitopes that could be recognized
by T-cells and induce an autoimmune response (Alghamdi
et al., 2019). An interesting finding has been that the
processing of citrullinated peptides depends on autophagy
induction in B-cells, whereas unmodified peptides are unaffected
when autophagy was blocked in this cell type with 3-
methyladenine (Ireland and Unanue, 2011). In particular,
citrullination of the MOG peptide at Arg46 protected this
peptide from degradation in EBV-infected B-cells. Interestingly,
Arg46 in MOG is positioned within the LIR motif that is
important for its selective targeting by autophagy (Birgisdottir
et al., 2013; Morandi et al., 2017). These findings suggest a
mechanistic link between EBV, autophagy, and autoimmunity.
EBV-infected B-cells indeed display more autophagosomes, and
MOG peptides are present inside these vesicles (Ireland and
Unanue, 2011; Morandi et al., 2017). Moreover, pharmacological
induction of autophagy with rapamycin further enhanced the
protection of citrullinated MOG peptides from degradation
(Camilli et al., 2016; Morandi et al., 2017), indicating that
this pathway protects myelin peptides against destructive
processing and consequently promotes their presentation to
T-cells. Altogether, EBV infection in B-cells is responsible
for inducing autophagy, which is important for altering
antigens that can initiate autoimmunity against myelin in
MS (Figure 2c).
In addition to the role in the generation and processing
of citrullinated peptides in EBV-infected B-cells, autophagy is
also important for B-cell survival, development, and activation
(Rathmell, 2012; Puleston and Simon, 2014; Bhattacharya and
Eissa, 2015), similarly to what happens in T-cells (see section
“T-Cells”). Thus, like DCs and T-cells, autophagy activation in
B-cells appears to contribute to the pathogenicity of MS rather
than to its prevention.
Neurons
Currently, axonal damage is considered part of a secondary
phase of MS, which is caused by an initial inflammation in
the periphery that is subsequently followed by demyelination
in the CNS (Ferguson et al., 1997; Trapp et al., 1998; Tsunoda
and Fujinami, 2002). This concept is known as the outside-
in model. However, this model is debated questioning whether
the axonal injury is exclusively caused by an immune response
initiated in the periphery or directly from the neurons. Moreover,
it cannot be excluded that neuronal loss is the primary phase
of MS, which is then followed by a second phase characterized
by demyelination and an inflammation response (Lovas et al.,
2000; Bjartmar et al., 2001; Tsunoda and Fujinami, 2002).
This scenario is known as the inside-out model. Infections in
neurons can indeed induce neuronal damage, which leads to
demyelination and neurodegeneration (Tsunoda et al., 2003),
and these observations support the inside-out model. However,
there are also examples from experiments with animal models of
MS that showed evidence of axonal injury without any signs of
demyelination (Ferguson et al., 1997; Trapp et al., 1998; Tsunoda
et al., 2003). Thus, it is possible that in addition to demyelination,
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other triggers are involved in the induction of neuronal loss
during MS (Tsunoda and Fujinami, 2002).
Neurons depend on autophagy for clearing misfolded or
aggregated proteins and damaged organelles, and autophagy is
continuously active at basal levels in neuronal cells under normal
conditions (Hara et al., 2006; Plaza-Zabala et al., 2017; Feng
et al., 2018; Stavoe and Holzbaur, 2019). Autophagy is active in
each neuronal compartment, however, the axons and dendrites
are the most metabolically demanding regions where autophagy
is crucial (Stavoe and Holzbaur, 2019). It is known that basal
autophagy in neurons is essential for protein quality control,
pruning, development, and neuronal survival (Hara et al., 2006;
Komatsu et al., 2006; Wong and Cuervo, 2010; Feng et al., 2017;
Plaza-Zabala et al., 2017; Stavoe and Holzbaur, 2019). Defects in
neuronal autophagy results in aggregate formation and neuronal
damage, which ultimately leads to neuronal death (Hara et al.,
2006; Komatsu et al., 2006, 2007; Liang and Le, 2015; Feng
et al., 2017; Stavoe and Holzbaur, 2019; Figure 2d). Defective
autophagy has been observed in the spinal cords of EAE mice,
and pharmacological induction of autophagy with rapamycin
reduced demyelination, inflammation, and neuronal loss (Feng
et al., 2017, 2018). In contrast, inhibition of autophagy non-
specifically with 3-methyladenine, resulted in higher neuronal
apoptosis in EAE mice (Feng et al., 2017), suggesting that
autophagy dysfunction could be associated with EAE-induced
neuronal loss. Another study showed that LC3 protein expression
levels in neurons were higher in control mice compared to
EAE mice (Feng et al., 2018), however, this could indicate
that autophagy is either reduced or enhanced in neurons
during EAE development. Future research has to reveal whether
neuronal autophagy contributes to the neurobiological and
neuropathological features of MS.
Microglia
Microglia are the tissue-resident macrophages of the CNS and
they form the first line of defense in the CNS (Schulz et al.,
2012; Kierdorf et al., 2013; Luo et al., 2017). Microglia get
activated upon tissue injury or a stimulus via a variety of
cell surface receptors (Augusto-Oliveira et al., 2019). Activated
microglia are essential for inflammatory responses in the CNS
(Ponomarev et al., 2005; Luo et al., 2017), where they are involved
in phagocytosis, antigen presentation, and cytokine production
(Benveniste, 1997). Microglia activation can result in either
neurotoxic or neuroprotective effects, depending on the stimulus
(Orihuela et al., 2016).
Activated microglia are present in CNS lesions of MS patients
and animal models, and are found to be an important source
of ROS and nitric oxide (NO) radicals (Gray et al., 2008; Zeis
et al., 2009). Interestingly, genes identified to be associated
with MS susceptibility are enriched in microglia compared to
other CNS cell types (Patsopoulos et al., 2019; Guerrero and
Sicotte, 2020), placing these cells in the spotlight of the disease.
Nowadays, microglia are recognized as one of the key players
in MS pathophysiology. However, the role of microglia in MS
is complex and controversial. Microglia are heterogeneous cells
that can adopt a range of different phenotypes, with different
functions, in response to different stimuli (Durafourt et al., 2012;
Melief et al., 2012, 2013; Boche et al., 2013; Giunti et al., 2014).
A few studies have shown that activated microglia participate
in both the inflammation state and demyelination, by secreting
pro-inflammatory cytokines (Prineas et al., 2001; Lassmann
et al., 2007; Luo et al., 2017). Microglia-deficient EAE mice are
protected against gray and white matter damage (Heppner et al.,
2005), and EAE severity is reduced (Bogie et al., 2014). Inhibition
of microglial activation in EAE mice also resulted in a reduction
of demyelination and preserved mature oligodendrocytes (OLs)
(further discussed in the next section) (Nissen et al., 2018).
Additionally, microglia-deficient mice showed a reduction in
myelin debris clearance, resulting in impaired remyelination
(Lampron et al., 2015). Microglia promote remyelination by
secreting anti-inflammatory cytokines, phagocytosing myelin
debris (Prineas et al., 2001; De Groot et al., 2001; Lassmann
et al., 2007; Kierdorf et al., 2013; Guerrero and Sicotte, 2020), and
enhancing OLs proliferation and differentiation (Li et al., 2005;
Voß et al., 2012; Miron et al., 2013; Bogie et al., 2014; Lloyd et al.,
2017). Taken together, microglia are involved in different phases
of MS, in which they play either a pathological or a protective role.
It has been postulated that autophagy is involved in
microglia-mediated neuroinflammation since there is evidence
that links autophagy to the regulation of microglial inflammation
(Plaza-Zabala et al., 2017). Autophagy induction in pre-
stimulated microglial cells with an inflammatory stimulus,
tumor necrosis factor α (TNF-α) or lipopolysaccharide (LPS),
promotes microglia toward an anti-inflammatory phenotype and
suppresses pro-inflammatory genes (Shao et al., 2014; Su et al.,
2016; Bussi et al., 2017; He et al., 2018; Jin et al., 2018; Hassanpour
et al., 2020). Conversely, autophagy inhibition leads to opposite
results, regardless of the presence of an inflammatory stimulus
(Shao et al., 2014; Su et al., 2016; Bussi et al., 2017; He et al.,
2018; Jin et al., 2018; Hassanpour et al., 2020). Moreover, Atg5
knockdown in microglia, enhances neurotoxicity in microglia-
neuron co-cultures (Bussi et al., 2017; He et al., 2018; Jin et al.,
2018), while autophagy induction by activating cannabinoid
receptor 2 prevents inflammasome activation in both EAE mice
(Shao et al., 2014) and microglia cultures (Shao et al., 2014; Su
et al., 2016). Together, these observations indicate that autophagy
is a key process in microglia as it balances their pro- and anti-
inflammatory responses (Figure 2e).
Besides the involvement of microglial autophagy in
inflammatory responses, ATG proteins are also involved in
the phagocytosis and elimination of myelin debris (Sanjuan
et al., 2007), which indicates the possible involvement of
LAP. As a result, defective ATG machinery in microglia could
lead to an inefficient clearing of myelin debris, which in
turn will cause impairment in remyelination and enhanced
neuroinflammation in neurodegenerative diseases (Sanjuan
et al., 2007; Meikle et al., 2008; Rangaraju et al., 2010). Altogether,
these observations emphasize the importance of microglial
autophagy and ATG proteins in general, in MS etiology since
they negatively modulate the underlying inflammatory response
and promote remyelination.
Microglia are also involved in synaptic pruning during
development. However, they also play a role in the synaptic
loss seen in neurodegenerative conditions, such as MS
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(Ramaglia et al., 2012). This action requires complement
C3 that localizes to synapses which are then recognized by
complement receptors expressed by microglia (Ramaglia et al.,
2012; Werneburg et al., 2020). Besides their importance in
synaptic pruning, these complement molecules are also involved
in microglia priming which leads to an exaggerated response to
a potentially minor secondary stimulus which is also connected
to MS. Interestingly, besides neuronal autophagy, autophagy in
microglia has also shown to control synaptic pruning (Druart
and Le Magueresse, 2019; Lieberman et al., 2019). Mice that
were Atg7-deficient specifically in microglia showed increased
spine density (Kim et al., 2017; Lieberman et al., 2019). One
of the hypotheses is that autophagy in microglia is important
for degrading the phagocytosed components by microglial cells
and this could be performed by LAP, which overlaps extensively
with the conventional autophagy pathway (Lieberman et al.,
2019). Both neuronal and microglial autophagy are involved in
synaptic development and dysfunction of this process might also
be involved in synaptic loss seen in MS. Further investigation is
required to reveal whether inflammation is the main cause of the
pathogenesis or whether dysfunction in autophagy causes both
inflammation and neurodegeneration.
Oligodendrocytes
In addition to microglia, activation of OLs are also important in
neuroinflammation and are involved in the development of MS
(Glass et al., 2010; Liang and Le, 2015).
Oligodendrocytes differentiate from oligodendrocyte
precursor cells (OPCs) and are important for the myelination of
axons in the CNS (Nave and Werner, 2014), where the extensive
loss of OLs has been observed in MS lesions (Wolswijk, 2000).
In MS, several processes result in the injury of both OLs and
OPCs, leading to demyelination and inefficient remyelination,
respectively (Chang et al., 2000; Wolswijk, 2002). Autophagy
is important for the survival and differentiation of OLs, and it
influences their myelinating ability (Bankston et al., 2019). The
enhancement of autophagy increases the thickness of the myelin
sheaths as well as the numbers of myelinated axons (Smith et al.,
2013). Moreover, autophagy-deficient OLs showed a reduction
in the number of myelinated axons and decreased thickness of
the myelin (Bankston et al., 2019). It has been suggested that
a key function of autophagy in OLs is to prevent aggregation
of myelin components, allowing OLs to continue with protein
and lipid synthesis to form compact myelin sheaths (Figure 2f;
Smith et al., 2013). Dysfunction of autophagy in OLs might
also play a role in the field of myelin plasticity, where it may be
involved in cytoplasm decompaction and decreased numbers
of myelin wraps due to lower levels of OLs that ultimately
leads to demyelination in MS (Hill et al., 2018; Belgrad et al.,
2020). However, the exact role of autophagy in OLs and whether
the disrupted OLs protein homeostasis in MS is caused by an
autophagy impairment, remain to be clarified.
Astrocytes
Another important cell type in MS are astrocytes, which
supports and regulates the communication between neurons
and maintains the blood-brain barrier. They also participate in
CNS damage repair by secreting growth factors and extracellular
matrix proteins (Joe et al., 2018). Several studies have shown
that astrocytes have multiple functions in the formation of MS
lesions, where they can be activated during the inflammatory
process and release inflammatory mediators that aggravate brain
lesions (Cotrina and Nedergaard, 2002; Cornejo et al., 2018;
Ponath et al., 2018; Cohen and Torres, 2019; Cressatti et al.,
2019). They can also recruit peripheral immune cells to the
inflammation site of the CNS (Rezai-Zadeh et al., 2009; Chompre
et al., 2013; Clarke et al., 2018). Astrocytes are also involved in the
repair of lesions, restricting the inflammatory damage (Sofroniew
and Vinters, 2010; Cho et al., 2014). Genetic astrocyte ablation
in MS mouse models aggravated tissue damage and clinical
impairment by both preventing the recruitment of microglia
to clear myelin debris and reducing the proliferation of OPCs
(Brambilla et al., 2009, 2005; Skripuletz et al., 2013). These events
result in impaired remyelination and shows the importance of
astrocytes in promoting tissue repair.
Autophagy in astrocytes is important for their differentiation
and maturation (Wang et al., 2014; Wang and Xu, 2020), and it is
implicated in the role of astrocytes in several neurodegenerative
diseases besides MS (Wang and Xu, 2020), including PD and AD.
In particular, autophagy in astrocytes is important in regulating
mitochondria dynamics and preserving mitochondrial network
organization during inflammation. Consequently, impairment of
this process results in the generation of ROS, which in turn
amplifies the pro-inflammatory response and ultimately leads
to the cell death of astrocytes (Lee et al., 2009; Motori et al.,
2013). Moreover, autophagy in astrocytes has also been linked
to neuronal survival since its inhibition with either rapamycin
or transduction with small interfering RNA against Atg5 induces
neuronal death (Figure 2f; Malta et al., 2012; Liu et al., 2018).
Together, these results underline the important role of autophagy
in astrocytes to maintain homeostasis in an inflammatory
environment, which contributes to neuronal survival. Whether
autophagy is dysregulated in astrocytes during MS needs to be
further investigated.
DISCUSSION
Defects in autophagy contribute to MS etiology. Autophagy,
however, acts as a two-edged sword during MS, having both
protective and detrimental effects that are cell type-dependent. As
highlighted in this review, autophagy enhancement in cell types
like DCs, T-cells, and B-cells, is participating to the initiation
of neuroinflammation seen in MS. Inhibition of autophagy in
these cells could be a potential therapeutic target. Yet, autophagy
also appears to be protective against the detrimental effects of
the immune system in neurons and glial cells, where it prevents
both aggregate and ROS formation, modulates the inflammatory
response, and promotes remyelination. To connect the role of
autophagy in MS to one of the paradigms in MS etiopathogenesis
(“inside-out” or “outside-in”) based on the current knowledge
is difficult. Autophagy is involved in both inflammation and
neurodegeneration processes that are seen in MS. The findings
that link autophagy to the pathology of DCs, T-cells, and B-cells,
could be considered as an “outside-in” event. However, the
functional role of autophagy in neurons which is affected in MS
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and clearance of myelin debris by glial cells could be considered
as an “inside-out” event. How the autophagy process is affected
in these different cell types is an important question that needs to
be answered in order to have a significant input in the ongoing
debate whether MS is an “inside-out” or “outside-in” event.
Thus, the available data suggest that autophagy plays an
important role in the regulation of the immune response under
normal conditions and in preventing the development of an
autoimmune response. This raises the possibility that modulating
the autophagy process in a cell type-specific manner may
limit inflammatory CNS damage and demyelination over the
course of MS, which in turn would protect against neuronal
death. It might be possible that the involvement of ATG
genes in the phagocytosis of extracellular myelin debris and
other components by DCs and microglia is rather due to
LAP. However, autophagy and LAP share numerous ATG
proteins, and therefore it is difficult to distinguish between
the two. One known difference between autophagy and LAP
is the requirement of ULK kinase complex in autophagy
and not in LAP (Lai and Devenish, 2012). Additionally,
ultrastructural observations of the phagosome membrane might
reveal the contribution and importance of these processes
in MS pathology.
In the optic of future therapies, it will be important to
elucidate whether autophagy modulation is beneficial in both
relapsing-remitting and progressive MS patients. However,
autophagy might be more therapeutically beneficial for relapsing-
remitting patients since this phase includes active inflammatory
demyelinating lesions, while this phenomenology is absent in
chronic progressive lesions (Dutta and Trapp, 2014).
Pharmacological interventions targeting autophagy in specific
cell types might help to restore the balance of the immune system,
which is a promising avenue for the treatment of autoimmune
disorders. Most of the current pharmacological modulators of
autophagy act on signaling cascades that regulate this process
(Figure 1), rather than specifically target autophagy itself. This
could result in off-target effects, which could be avoided by giving
the treatment in cycles of brief periods. On the other hand, more
direct biochemical approaches to modulate autophagy such as
spermidine (Morselli et al., 2011) and TAT-beclin (Shoji-Kawata
et al., 2013), are promising for the treatment of MS as they are also
less invasive. Moreover, caloric restriction or exercise enhances
autophagy and therefore might be effective as a treatment for MS
(Choi et al., 2016).
Based on the current knowledge about the involvement of
autophagy in different cell types during MS, T-cells and microglia
are promising targets for cell type-specific delivery of autophagy
modulators (Zhang F. et al., 2016; Schmid et al., 2017; Wang
et al., 2019). In this context, nanoparticles that specifically
bind to particular T-cell subsets have been designed (Schmid
et al., 2017), and inhibiting autophagy in CD4+ and CD8+
autoreactive T-cells could prevent the initial activation of the
immune response seen in MS. Since prolonged inhibition of
autophagy in T-cells might negatively affect T-cell homeostasis,
transient therapy is desirable. In addition, autophagy inducers
in nanoparticles that are specifically targeted to microglia and
macrophages (Wang et al., 2019) could selectively promote
both anti-inflammatory responses and dampening of the pro-
inflammatory effects, which will ultimately result in beneficial
effects on the inflammation resolution, clearing of myelin debris,
and remyelination. However, additional research is needed to
investigate whether a nanoparticle or any other approach to
either block or stimulate autophagy in a cell type-specific manner
can delay MS progression. Nonetheless, autophagy is an attractive
and promising target for the development of new treatments
for MS and future studies investigating the precise role of this
pathway in the different cell types during the course of this severe
disease will be key to appropriately intervene therapeutically.
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